Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Brooks Laboratories's annualized net income for the quarter that ended in Mar. 2026 was ₹60.9 Mil. Brooks Laboratories's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹1,226.6 Mil. Therefore, Brooks Laboratories's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 4.97%.
The historical rank and industry rank for Brooks Laboratories's Return-on-Tangible-Equity or its related term are showing as below:
NSE:BROOKS'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -28.14 Med: -17.73 Max: 22.27
Current: 21.92
During the past 13 years, Brooks Laboratories's highest Return-on-Tangible-Equity was 22.27%. The lowest was -28.14%. And the median was -17.73%.
NSE:BROOKS's Return-on-Tangible-Equity is ranked better than 80.76% of 899
companies
in the Drug Manufacturers industry
Industry Median: 7.87
vs NSE:BROOKS: 21.92
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Brooks Laboratories Return-on-Tangible-Equity Related Terms
Brooks Laboratories Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Brooks Laboratories's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:BROOKS vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Brooks Laboratories's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brooks Laboratories Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Brooks Laboratories's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Brooks Laboratories's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 4.97% mean?
Brooks Laboratories (NSE:BROOKS) has a Return-on-Tangible-Equity of 4.97% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Brooks Laboratories and its competitors. According to the industry distribution chart, Brooks Laboratories ranks #173 out of 899 companies in the Drug Manufacturers industry, placing it in the top 19.2%.
Is Brooks Laboratories' Return-on-Tangible-Equity too high?
Brooks Laboratories' current Return-on-Tangible-Equity is 4.97%. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.87. Brooks Laboratories' value of 4.97% is 36.8% below this industry median. Based on the distribution chart, Brooks Laboratories ranks #173 out of 899 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Brooks Laboratories has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Brooks Laboratories' Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Brooks Laboratories ranks #173 out of 899 companies for Return-on-Tangible-Equity. This places Brooks Laboratories in the top 19% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.87. Brooks Laboratories' value of 4.97% is 36.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.87, based on 899 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Brooks Laboratories's current Return-on-Tangible-Equity of 4.97% is 36.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Brooks Laboratories and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brooks Laboratories's current Return-on-Tangible-Equity is 4.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brooks Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Brooks Laboratories (NSE:BROOKS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹117.12, compared to a current price of ₹60.29 — trading 48.5% below its estimated fair value. The current Return-on-Tangible-Equity is 4.97% and 36.8% below the Drug Manufacturers industry median of 7.87. Brooks Laboratories' overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Brooks Laboratories (NSE:BROOKS), the current Return-on-Tangible-Equity is 4.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Brooks Laboratories (NSE:BROOKS) Overvalued in 2026?
Based on GuruFocus' analysis, Brooks Laboratories stock appears to be undervalued.
The current stock price of ₹60.29 is trading 48.5% below its estimated GF Value™ of ₹117.12.
GuruFocus considers Brooks Laboratories to be Significantly Undervalued.
Key valuation signals for NSE:BROOKS:
Return-on-Tangible-Equity: 4.97%
GF Value™: ₹117.12 vs. price of ₹60.29 (48.5% below fair value)
Industry Position: 36.8% below the Drug Manufacturers median (#173 of 899)
No single metric tells the full story. See the NSE:BROOKS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Brooks Laboratories Ltd is a pharmaceutical manufacturer focused on developing and producing a broad range of generic medicines. Its key segments include injectables, tablets, and dry syrups, with product lines covering antibiotics such as beta-lactams and cephalosporins as well as general critical care injectables. The company operates manufacturing facilities compliant with international quality standards located in India, serving both domestic and international markets. Revenue is generated through contract manufacturing and sales of pharmaceutical formulations distributed broadly across regulated and semi-regulated international markets. The company has obtained regulatory certifications from multiple countries to comply with international standards for pharmaceutical manufacturing.
60GF Score
Get the complete analysis for NSE:BROOKS
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BROOKS has been successfully added to your 
